rHuPH20
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VITRASE | — | 2004-05-05 | fda.gov ↗ |
Trials 69 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT07697274 | Sep 2026 → Sep 2027 expected | cutaneous sclerosis, systemic sclerosis | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06854380 | Jan → Jul 2026 overdue | voice disorders | Mansoura University | Recruiting | No outcome recorded |
| Phase 0 | NCT06839391 | Mar 2025 → Mar 2026 overdue | — | Benha University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05995626 | Mar → Sep 2024 | scleroderma | University of Nebraska | Completed | No outcome recorded |
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT04656704 | Jan 2020 → Jan 2022 | CREST syndrome, localized scleroderma, scleromyxedema | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| Phase 0 | NCT01945099 | Sep 2013 → Dec 2015 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT01722916 | Oct 2012 → Feb 2022 | — | Northwestern University | Completed | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT07484893 | May → Aug 2026 overdue | — | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06980363 | Jun → Aug 2025 overdue | — | Fayoum University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04484337 | Jul 2020 → May 2023 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT03864419 | Oct 2019 → Jul 2023 | Burkitt lymphoma, diffuse large B-cell lymphoma, multicentric Castleman disease | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT04920370 | Sep 2019 → Nov 2021 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05396742 | Aug 2018 → May 2019 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03538626 | Jun 2018 → Aug 2022 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02667223 | Feb → Jul 2016 | hyperlipoproteinemia | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02654522 | Jan → Feb 2016 | — | Steve Yoelin M.D. Medical Associates, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02199028 | Jul 2014 → Mar 2015 | type 1 diabetes mellitus | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01572012 | Feb 2012 → Nov 2013 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00979875 | Sep 2009 → Feb 2010 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00862849 | Mar → Jun 2009 | diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00807963 | Dec 2008 → Sep 2009 | osteoporosis | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00803972 | Nov 2008 → Aug 2009 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00782587 | Oct 2008 → Mar 2009 | superficial urinary bladder carcinoma | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00493220 | Jun → Sep 2007 | — | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00435604 | Feb → May 2007 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06697197 | Feb 2025 → Jan 2029 expected | cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01928030 | Dec 2013 → Nov 2015 | cancer, lymphedema | Stanford University | Terminated | No outcome recorded |
| Phase 1/2 | NCT00782106 | Dec 2006 → Nov 2007 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 1/2 | NCT00318643 | Mar 2006 → Aug 2009 | urinary bladder cancer | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT06718413 | Mar 2025 → Aug 2027 expected | stroke disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT03306615 | Oct 2021 → Jun 2026 overdue | — | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01987609 | Jul 2015 → Mar 2017 | psoriasis | Tissa Hata, MD | Completed | No outcome recorded |
| Phase 2 | NCT02265575 | Oct 2014 → Dec 2016 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01756157 | Feb → Sep 2013 | hereditary angioedema | Shire | Completed | No outcome recorded |
| Phase 2 | NCT01689363 | Sep → Nov 2012 | hypersensitivity reaction disease | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01426763 | Sep → Nov 2011 | hereditary angioedema | Shire | Completed | No outcome recorded |
| Phase 2 | NCT01194245 | Aug 2010 → Aug 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01194258 | Aug 2010 → Aug 2011 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00928447 | Jun → Sep 2009 | contact dermatitis due to nickel | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00774800 | Oct 2008 → Mar 2009 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07000058 | Jun → Dec 2025 overdue | — | Misr University for Science and Technology | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05083663 | Sep → Nov 2021 | — | Sohag University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01485796 | Dec 2011 → Jan 2013 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05084053 | Jan 2022 → Oct 2025 | chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT04071457 | Aug 2019 → Jul 2029 expected | plasma cell myeloma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02955355 | Nov 2016 → Jul 2023 | chronic inflammatory demyelinating polyradiculoneuropathy | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT00814320 | Dec 2008 → Nov 2010 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT00593281 | Jan → Oct 2006 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00000493 | Sep 1977 → Dec 1985 | coronary artery disorder, myocardial infarction, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT05511428 | Nov 2022 → May 2024 | plasma cell myeloma | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT05466604 | Dec 2019 → Jun 2022 | infectious disease | Hacettepe University | Completed | No outcome recorded |
| Phase 4 | NCT03662334 | Oct 2013 → Feb 2014 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01526733 | Dec 2011 → Aug 2012 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01116102 | May 2010 | — | Baxter Healthcare Corporation | Terminated | No outcome recorded |
| Phase 4 | NCT01120431 | May 2010 | — | Baxter Healthcare Corporation | Withdrawn | No outcome recorded |
| Phase 4 | NCT01139294 | Feb 2010 → Nov 2011 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00807885 | Dec 2008 → Jan 2009 | — | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00477152 | Aug 2007 → Jun 2008 | — | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00311519 | Nov 2005 → Jan 2006 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07101016 | Aug 2025 overdue | periapical periodontitis | Mariam Hesham Mahmoud Abdelfattah Eissa | Not yet recruiting | No outcome recorded |
| — | NCT07436546 | Mar → Dec 2025 | impacted teeth, multiple | Postgraduate Institute of Dental Sciences Rohtak | Completed | No outcome recorded |
| — | NCT05671172 | May 2023 → Jan 2024 | — | Benha University | Completed | No outcome recorded |
| — | NCT07411950 | Jan 2021 → May 2025 | chronic pain syndrome, radiculopathy | EPC Education s.r.o. | Completed | No outcome recorded |
| — | NCT03266406 | Sep 2017 → Sep 2018 | ocular hypotension | Assiut University | Unknown | No outcome recorded |
| — | NCT02885259 | Sep 2016 → Dec 2017 | multifocal motor neuropathy | UMC Utrecht | Unknown | No outcome recorded |
| — | NCT02293083 | Apr 2010 → Apr 2011 | myofascial pain syndrome | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00547664 | Jan 2008 → Dec 2009 | — | HPC Healthcare, Inc. | Completed | No outcome recorded |
| — | NCT02059694 | ? → Jul 2015 | — | Duke University | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 74 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05344495 Comparator | Jan → Jul 2022 | neuropathy, painful | Minia University | Unknown | No outcome recorded |
| Phase 0 | NCT03411330 Comparator | Jan 2017 → Apr 2018 | — | Cairo University | Completed | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT07391670 Background | Mar 2026 → Aug 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07161414 Background | Nov 2025 → Jul 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06622005 Background | Apr 2025 → Apr 2027 expected | plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT07667322 Background | Dec 2024 → Feb 2028 expected | multiple sclerosis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT06511570 Background | Jun → Sep 2024 | Alzheimer disease | Acumen Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06310551 Background | Mar 2024 → Jan 2028 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 1 | NCT05418868 Background | Jun 2022 → Jun 2027 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 1 | NCT05293249 Background | May 2022 → Jun 2025 | — | Pablo Tebas | Completed | No outcome recorded |
| Phase 1 | NCT05004259 Background | Mar 2022 → Sep 2024 | hemolytic anemia | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT05291520 Background | Feb 2022 → Apr 2023 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04606381 Background | Nov 2020 → Jul 2024 overdue | neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04532125 Background | Aug 2020 → Aug 2022 | — | argenx | Completed | No outcome recorded |
| Phase 1 | NCT04311710 Background | Jun 2020 → Jan 2021 | neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT04112498 Background | Oct 2019 → Feb 2023 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03972306 Background | Aug 2019 → Jun 2025 | multiple sclerosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04073589 Background | Jul → Sep 2019 | — | argenx | Completed | No outcome recorded |
| Phase 1 | NCT03320707 Background | Oct 2017 → Aug 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03242889 Background | Aug → Nov 2017 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT02519452 Background | Oct 2015 → Dec 2017 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02217917 Background | Oct 2015 → Apr 2016 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT01275131 Comparator | Jan → Dec 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00705536 Comparator | Dec 2007 → Feb 2008 | diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT05455697 Background | Jan 2023 → Oct 2026 expected | high grade B-cell lymphoma | University of Washington | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05205252 Comparator | Dec 2021 → Jul 2023 | refractory hematologic cancer | Epizyme, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03837509 Background | Sep 2019 → Apr 2022 | refractory plasma cell neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT03656718 Background | Oct 2018 → Sep 2022 | neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT03446040 Background | Mar 2018 → Aug 2024 | cancer of unknown primary site | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/2 | NCT02754141 Background | Jun 2016 → Oct 2021 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07527806 Background | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07485647 Background | May 2026 → May 2028 expected | plasma cell myeloma | Eden Biltibo | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07042295 Background | Mar 2026 → Feb 2029 expected | skin squamous cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05730712 Background | Mar 2024 → Apr 2025 | castration-resistant prostate carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT05886036 Comparator | Jan 2024 → Oct 2026 expected | nodular lymphocyte predominant Hodgkin lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06101134 Background | Nov 2023 → Apr 2025 overdue | melanoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05996471 Background | Aug 2023 → May 2026 overdue | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05289687 Background | May 2023 → Jun 2027 expected | T-cell acute lymphoblastic leukemia | Eastern Cooperative Oncology Group | Recruiting | No outcome recorded |
| Phase 2 | NCT07370233 Comparator | Feb 2023 → Mar 2025 | vertebral column disorder | Benha University | Completed | No outcome recorded |
| Phase 2 | NCT05498220 Background | Feb 2023 → Mar 2025 | diffuse large B-cell lymphoma | UNC Lineberger Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT05340309 Background | Dec 2022 → Dec 2026 expected | non-small cell lung carcinoma | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04150692 Background | Jan 2021 → Mar 2026 | plasma cell myeloma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT04311606 Comparator | Nov 2020 → Dec 2024 | euthyroid Graves orbitopathy | Massachusetts Eye and Ear Infirmary | Completed | No outcome recorded |
| Phase 2 | NCT04070378 Background | Nov 2019 → Jun 2023 | Alzheimer disease | Marc L Gordon, MD | Completed | No outcome recorded |
| Phase 2 | NCT03467867 Background | Apr 2018 → Dec 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Georgetown University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00916357 Comparator | Jul → Nov 2009 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00883558 Background | May 2009 → Feb 2010 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05523167 Background | Oct 2022 → Dec 2026 expected | antisynthetase syndrome, dermatomyositis, immune-mediated necrotizing myopathy | argenx | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04799275 Background | May 2021 → Mar 2027 expected | T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, diffuse large B-cell lymphoma with chronic inflammation +5 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT07388524 Background | Mar 2027 → Sep 2032 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT06337318 Background | Oct 2024 → Mar 2032 expected | follicular lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT05625399 Background | Mar 2023 → Aug 2025 overdue | melanoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05256225 Background | Nov 2022 → Oct 2027 expected | carcinosarcoma of the corpus uteri, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma +2 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT05513586 Background | Sep 2022 → Oct 2025 | immunodeficiency disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT05297565 Background | Aug 2022 → Feb 2024 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT05415215 Background | Jul 2022 → Nov 2024 | female breast carcinoma, inflammatory breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04810078 Background | May 2021 → Jul 2025 overdue | clear cell renal carcinoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03735121 Background | Dec 2018 → Apr 2022 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03301220 Background | Nov 2017 → May 2024 | smoldering plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03277313 Background | Sep 2017 → Jul 2022 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT04347733 Comparator | May 2017 → Mar 2019 | frozen shoulder | Veterans Health Service Medical Center, Seoul, Korea | Completed | No outcome recorded |
| Phase 3 | NCT02549170 Background | Dec 2015 → Feb 2022 | chronic inflammatory demyelinating polyradiculoneuropathy | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT01875367 Background | Sep 2013 → Nov 2016 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT01175213 Background | Jul 2010 → Aug 2013 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT03824665 Background | Feb → May 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03243500 Comparator | May 2015 → May 2016 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00773175 Comparator | Oct 2008 → Nov 2009 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT00656370 Background | Dec 2007 → Jan 2008 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01719978 Comparator | Oct 2007 | cardiac rhythm disease | Mauricio Jose Tornelli | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07298746 Comparator | Dec 2025 → Dec 2026 expected | — | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07141589 Comparator | Aug 2024 → Nov 2025 overdue | — | Cairo University | Recruiting | No outcome recorded |
| — | NCT03660020 Comparator | May 2018 → Nov 2020 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT03436836 Comparator | Jan → Feb 2018 | — | Cairo University | Completed | No outcome recorded |
| — | NCT03101033 Background | May 2015 → Feb 2016 | lumbar disk disease | yan lu | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-10-29 | Pfizer | HALOZYME ANNOUNCES FIRST CLINICAL DOSING OF PFIZER’S RIVIPANSEL USING ENHANZE™TECHNOLOGY pfizer.com ↗ |
| 2012-12-21 | Pfizer | Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase pfizer.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 148 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHuPH20 | “Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once...” NCT03837509 ↗58“Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC)...” NCT04606381 ↗ “Co-administration with recombinant human hyaluronidase (rHuPH20), topical nonsteroidal anti-inflammatory drug, or topical steroid was evaluated for some SC injections.” PMID 40296638 ↗ Apr 2025 “Study Medications Hylenex recombinant (hyaluronidase human injection); rHuPH20 (Hylenex is a registered trademark of Baxter International, Inc. or its subsidiaries)” NCT00311519 ↗ “1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection” NCT03301220 ↗ “Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02549170 ↗ “Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02955355 ↗ “Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks” NCT03242889 ↗ “The investigational medication to be studied is an enzyme called ChemophaseTM (recombinant human hyaluronidase, rHuPH20).” NCT00318643 ↗ “TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20).” NCT05084053 ↗ “recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20)” NCT00782587 ↗ “Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion.” NCT02217917 ↗ “Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer” NCT05523167 ↗ “Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)” NCT05513586 ↗ “recombinant human hyaluronidase (rHuPH20)-facilitated subcutaneous rehydration” PMID 19805455 ↗ Oct 2009 “recombinant hyaluronidase (rHuPH20) as an adjunctive for local anaesthesia” NCT02059694 ↗ “recombinant human hyaluronidase (rHuPH20) increases SC tissue permeability” PMID 22846381 ↗ Jul 2012 “Recombinant Human Hyaluronidase [rHuPH20]) SC Administration” NCT02519452 ↗ “recombinant human hyaluronidase (rhuph20, Pf 06744547)” NCT02667223 ↗ “Drug: Recombinant human hyaluronidase PH20 (rHuPH20)” NCT01275131 ↗ “daratumumab 1800 mg with rHuPH20 30,000 units” NCT04070378 ↗ “Drug: ENHANZE (rHuPH20)” NCT04311710 ↗ “Drug: rHuPH20” NCT03972306 ↗ “rHuPH20” NCT01928030 ↗ |
| Known as | Chemophase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00318643 ↗ |
| Known as | ChemophaseTM | “The investigational medication to be studied is an enzyme called ChemophaseTM (recombinant human hyaluronidase, rHuPH20).” NCT00318643 ↗ |
| Known as | ENHANZE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04311710 ↗ |
| Known as | H-LASE | “hyaluronidase (H-LASE®, 1500 iu” NCT02293083 ↗ |
| Known as | HLXTE-HAase02 | “HLXTE-HAase02 is a proprietary recombinant human hyaluronidase, with a molecular weight of approximately 49 kDa, is expressed in Chinese Hamster Ovary (CHO) cells and is...” NCT07484893 ↗ |
| Known as | human recombinant hyaluronidase | “morphine administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX) and intravenously” NCT00593281 ↗ |
| Known as | Hyalase | “Hyaluronidase: 1 mL of gel prepared by dissolving the contents of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and then incorporating 1 mL of this...” NCT07101016 ↗ |
| Known as | hyaluronidase | “Hyaluronidase: 1 mL of gel prepared by dissolving the contents of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and then incorporating 1 mL of this...” NCT07101016 ↗44“Hyaluronidase, or Hylenex, is not an investigational drug; it is FDA-approved, regularly used in the U.S., and will be procured for this study through the pharmacy of the...” NCT02265575 ↗ “Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device.” NCT01875367 ↗ “All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive” NCT03824665 ↗ “Advanced Touhy needle delivery of 80 mg triamcinolone and 1500 IU hyaluronidase into the epidural space to target inflammation and adhesions” NCT07370233 ↗ “600 mg Pertuzumab, 600 mg Trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days” NCT07527806 ↗ “bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.” NCT05344495 ↗ “hyaluronidase (H-LASE®, 1500 iu” NCT02293083 ↗ “hyaluronidase (1,500 IU)” NCT07411950 ↗ |
| Known as | Hyaluronidase Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03864419 ↗ |
| Known as | hyaluronidase human injection | “Study Medications Hylenex recombinant (hyaluronidase human injection); rHuPH20 (Hylenex is a registered trademark of Baxter International, Inc. or its subsidiaries)” NCT00311519 ↗ |
| Known as | Hyaluronidase-fihj | “-Subcutaneous daratumumab and hyaluronidase-fihj” NCT04150692 ↗ |
| Known as | Hyaluronidase-oysk | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05256225 ↗ |
| Known as | Hyaluronidase-zzxf | “Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf” NCT05415215 ↗ |
| Known as | Hylenex | “Hyaluronidase, or Hylenex, is not an investigational drug; it is FDA-approved, regularly used in the U.S., and will be procured for this study through the pharmacy of the...” NCT02265575 ↗14“morphine administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX) and intravenously” NCT00593281 ↗ “Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)” NCT00656370 ↗ “Hyaluronidase (Hylenex)” NCT07697274 ↗ |
| Known as | Hylenex recombinant | “Study Medications Hylenex recombinant (hyaluronidase human injection); rHuPH20 (Hylenex is a registered trademark of Baxter International, Inc. or its subsidiaries)” NCT00311519 ↗3“Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration” NCT01572012 ↗ “Hylenex recombinant (for short, Hylenex) in subcutaneous (SC) injection” NCT00547664 ↗ “Recombinant DNA-based hyaluronidase (RDNAH/Hylenex recombinant)” NCT02654522 ↗ |
| Known as | Hynidase | “Intralesional injection of steroids (betamethasone), (Betafos®) and hyaluronidase (enzyme), (Hynidase®) into benign vocal fold lesions” NCT06854380 ↗ |
| Known as | pf 06744547 | “A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of...” NCT02217917 ↗1“recombinant human hyaluronidase (rhuph20, Pf 06744547)” NCT02667223 ↗ |
| Known as | RDNAH | “Recombinant DNA-based hyaluronidase (RDNAH/Hylenex recombinant)” NCT02654522 ↗ |
| Known as | recombinant human hyaluronidase | “1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection” NCT03301220 ↗24“Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02549170 ↗ “Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02955355 ↗ “The investigational medication to be studied is an enzyme called ChemophaseTM (recombinant human hyaluronidase, rHuPH20).” NCT00318643 ↗ “TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20).” NCT05084053 ↗ “Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)” NCT03277313 ↗ “recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20)” NCT00782587 ↗ “Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)” NCT05513586 ↗ “with Recombinant Human Hyaluronidase \[rHuPH20\] 30,000 units \[U\]” NCT03242889 ↗ “durvalumab + recombinant human hyaluronidase (rHu) dose” NCT07391670 ↗ “recombinant human hyaluronidase (rhuph20, Pf 06744547)” NCT02667223 ↗ “recombinant human hyaluronidase (rHuPH20)” NCT03662334 ↗ |
| Known as | recombinant human hyaluronidase PH20 | “part 1, 20 mg/kg SC + recombinant human hyaluronidase PH20 [rHuPH20] 2,000 U/mL; part 2, 60 mg/kg IV; part 3, 3,000 mg SC + rHuPH20 2,000 U/mL” PMID 40698814 ↗ Jul 202512“Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP).” NCT03538626 ↗ “daratumumab co-formulated with recombinant human hyaluronidase PH20” PMID 32915384 ↗ Sep 2020 “recombinant human hyaluronidase PH20 (rHuPH20)” NCT04073589 ↗ “Recombinant Human Hyaluronidase PH20 (rHuPH20)” NCT05418868 ↗ |
| Known as | rHu | “durvalumab + recombinant human hyaluronidase (rHu) dose” NCT07391670 ↗1“Recombinant Human Hyaluronidase (rHu)” NCT07161414 ↗ |
| Known as | rHuPH20 = Recombinant Human Hyaluronidase | “rHuPH20 = Recombinant Human Hyaluronidase” NCT00782106 ↗ |
| Known as | Sine | “Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and...” NCT03101033 ↗ |
| Modality | Protein / enzyme biologic | “an enzyme called hyaluronidase, and is a human recombinant form of the enzyme” NCT00311519 ↗ |
| Route | Subcutaneous | “Each subject will receive a SC infusion” NCT00311519 ↗ |